=========================== JeffNEWS, February 21, 1995 =========================== How `Antisense' Gene Therapy for Restenosis Works ------------------------------------------------- The research carried out by Andrew Zalewski, MD, research director, division of cardiology, and Yi Shi, MD, PhD, assistant research director, cardiology, to treat restenosis is part of the new biotechnology called "antisense." Antisense technology tries to halt disease by stopping, or temporarily suspending, the activating energy of genes that cause the disease. In this case, Drs. Zalewski and Shi identifed one gene stimulating the growth of scar tissue on the inner walls of arteries recently cleared by balloon angioplasty. The gene which Drs. Zalewski and Shi identified early in their research as stimulating restenosis is known as the "c-myc" gene. They found that the effect on artery walls of balloon angioplasty activates the c-myc gene, which in turn stimulates growth of smooth muscle cells. This produces scar tissue on the arteries' inner walls, narrowing the arteries and blocking or slowing the blood flow through them. Their key finding was to discover that the action of the c-myc gene could be "blocked" by using pieces of synthetic DNA called antisense "oligomers." This blocking inhibits cell growth and secretion of collagen, major components of the scar tissue. When the oligomers are delivered into the vessel wall, the growth of soft-muscle scar tissue halts. In this particular research, the oligomers are the "antisense" agents. The blocking is achieved by administering the antisense oligomers to the c-myc gene's so-called "messenger RNA." When that occurs genetically, the binding effect is analogous to putting a padlock on the c-myc gene, so that it can't activate the smooth-muscle cells in artery walls to build up and slow blood flow. ------------------------------------------------------------------------------ Information provided by: Editor, JeffNEWS (215) 955-6204 ------------------------------------------------------------------------------